David A. Lowe


Dr. David Lowe is President and CEO of NeuroAssets, a Geneva-based neuroscience consulting company working with pharma, biotech, venture capital and not-for-profit organisations on neurotherapeutics and diagnostics.  Dr. Lowe is also Adjunct Professor of Neuroscience in the Icahn School of Medicine at Mount Sinai in New York.

Earlier in his career David headed large CNS R&D groups in pharma at Sandoz Ltd. (now Novartis), Bayer and Roche.  His experience includes private and public companies as well as venture capital, with more than 35 years’ experience in CNS drug discovery, translational medicine and product development, initiating and implementing collaborations between pharma, biotech, and academia, with an established track record of generating diverse clinical candidates that moved into clinical trials and the market.

In addition to his consulting work, Dr. Lowe is currently a member of the Board of Directors of Amarantus Bioscience Holdings, Inc. and Delos Pharmaceuticals.

Dr. Lowe has a successful record in neuroscience biotech companies as CSO and EVP of PsychoGenics Inc.; CSO and Board Director of Memory Pharmaceuticals (acquired by Hoffman-La Roche, Inc.); EVP and Founding CSO of Fidelity Biosciences; and President and CEO of EnVivo Pharmaceuticals Inc., a Fidelity company recently renamed Forum Pharmaceuticals.


  • BSc with honors, University of Bristol
  • PhD, Neurobiology, University of Leeds


  • Member, Buck Advisory Council, The Buck Institute for Research on Aging
  • Board Member, Amarantus Bioscience Holdings, Inc.
  • Board Member, Delos Pharmaceuticals
Change text size: